In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Immunogen Inc (NASDAQ:IMGN) reported that Primecap Management Co/ca/ has picked up 6,606,643 of common stock as of 2016-12-06.
The acquisition brings the aggregate amount owned by Primecap Management Co/ca/ to a total of 6,606,643 representing a 7.57% stake in the company.
For those not familiar with the company, ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
A glance at Immunogen Inc (NASDAQ:IMGN)’s key stats reveals a current market capitalization of $182.97 million based on 87.30 million shares outstanding and a price at last close of $1.96 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-08, Enyedy picked up 25,000 at a purchase price of $1.83. This brings their total holding to 100,100 as of the date of the filing.
On the sell side, the most recent transaction saw Lambert unload 3,889 shares at a sale price of $8.22. This brings their total holding to 106,857.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Immunogen Inc (NASDAQ:IMGN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.